Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: A systematic review

Current Pharmaceutical Design

Volumn 20, Issue 4, 2014, Pages 513-528

  Brezinski, Elizabeth A ^a   Follansbee, Matthew R ^a   Armstrong, Ehrin J ^a   Armstrong, April W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adalimumab; Cardiovascular disease; Endothelial dysfunction; Etanercept; Infliximab; Psoriasis; Psoriatic arthritis; Systematic review; TNF inhibitors

Indexed keywords

ADALIMUMAB; ETANERCEPT; GLYCERYL TRINITRATE; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; COMORBIDITY; CROSS-SECTIONAL STUDY; DATA BASE; ELASTICITY; ENDOTHELIAL DYSFUNCTION; HUMAN; LONGITUDINAL STUDY; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PULSE WAVE; REVIEW; SCIENCE; SYSTEMATIC REVIEW; TONOMETRY; VASODILATATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SYSTEMIC VASCULITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84894095018     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282004140213123852     Document Type: Review

References (76)

1. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141(12): 1537-41.
2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9(2): 136-9.
3. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26(4): 314-20.
4. Catanoso M, Pipitone N, Salvarani C. Epidemiology of psoriatic arthritis. Reumatismo 2012; 64(2): 66-70.
5. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53(4): 573.
6. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270(2): 147-57.
7. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31(8): 1000-6.
8. Zhu TY, Li EK, Tam LS. Cardiovascular risk in patients with psoriatic arthritis. Int J Rheumatol 2012; 2012: 714321.
9. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20(4): 303-7.
10. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. A tale of two plaques: convergent mechanisms of T-cellmediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 2011; 20(7): 544-9.
11. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 2011; 63(1): 1-9.
12. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63(1): 40-6.
13. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162(3): 633-6.
14. Schon MP, Boehncke WH, Brocker EB. Psoriasis: Clinical manifestations, pathogenesis and therapeutic perspectives. Discov Med 2005; 5(27): 253-8.
15. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008; 214(2): 149-60.
16. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16): 1685-95.
17. Hunt BJ. The endothelium in atherogenesis. Lupus 2000; 9(3): 189-93.
18. Ablin JN, Goldstein Z, Aloush V, et al. Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis. Rheumatol Int 2009; 29(3): 257-62.
19. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012; 71(3): 319-26.
20. Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 2012; 18(11): 1543-55.
21. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113(5): 664-70.
22. Costa L, Caso F, D'Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 2012; 31(4): 711-5.
23. Yiu KH, Yeung CK, Chan HT, et al. Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. Br J Dermatol 2011; 164(3): 514-20.
24. Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 2009; 218(2): 110-3.
25. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009; 120(6): 502-9.
26. De Simone C, Di Giorgio A, Sisto T, et al. Endothelial dysfunction in psoriasis patients: cross-sectional case-control study. Eur J Dermatol 2011; 21(4): 510-4.
27. Ulusoy RE, Karabudak O, Yokusoglu M, Kilicaslan F, Kirilmaz A, Cebeci BS. Noninvasive assessment of impaired endothelial function in psoriasis. Rheumatol Int 2010; 30(4): 479-83.
28. Karadag AS, Yavuz B, Ertugrul DT, et al. Is psoriasis a preatherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol 2010; 49(6): 642-6.
29. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57(2): 287-93.
30. Balci DD, Balci A, Karazincir S, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 2009; 23(1): 1-6.
31. Lo Nigro A, Ramonda R, Contessa C, et al. Subclinical atherosclerosis in patients with psoriatic arthritis: a matchedcontrol study [abstract]. Ann Rheum Dis 2009; 68(Suppl3): 662.
32. Usta M, Yurdakul S, Aral H, et al. Vascular endothelial function assessed by a noninvasive ultrasound method and serum asymmetric dimethylarginine concentrations in mild-to-moderate plaque-type psoriatic patients. Clin Biochem 2011; 44(13): 1080-4.
33. Martyn-Simmons CL, Ranawaka RR, Chowienczyk P, et al. A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. Br J Dermatol 2011; 164(1): 26-32.
34. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intimamedia thickness: a systematic review and meta-analysis. Circulation 2007; 115(4): 459-67.
35. de Groot E, Hovingh GK, Wiegman A, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004; 109(23 Suppl 1): III33-8.
36. Enany B, El Zohiery AK, Elhilaly R, Badr T. Carotid intima-media thickness and serum leptin in psoriasis. Herz 2012; 37(5): 527-33.
37. El-Mongy S, Fathy H, Abdelaziz A, et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol 2010; 24(6): 661-6.
38. Arias-Santiago S, Orgaz-Molina J, Zubiaur M, Rodriguez G. S100A9 and S100A8 gene expression levels in patients with psoriasis [abstract]. J Am Acad Dermatol 2012; 66(4): AB202.
39. Arias-Santiago S, Almazan-Fernandez F, Sancho-Lopez J, Ruiz-Carrascosa JC, Castellote-Caballero L. Cardiovascular risk and cytokines profile in patients with severe psoriasis [abstract]. J Am Acad Dermatol 2010; 62(3): AB127.
40. Atzeni F, Sarzi-Puttini P, Sitia S, et al. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol 2011; 38(8): 1661-4.
41. Kimhi O, Caspi D, Bornstein NM, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007; 36(4): 203-9.
42. Eder L, Zisman D, Barzilai M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008; 35(5): 877-82.
43. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57(6): 1074-80.
44. Youssef SS, Hosny S, Bakr I, Youssef A. Susceptibility to Atherosclerosis in Patients with Psoriasis and Psoriatic Arthritis as Determined by Increased Carotid Artery Intima-Media Thickness. Journal of Pan-Arab League of Dermatologists 2009; 20(1): 159-72.
45. Margro-Checa C, Orgaz-Molina J, Rosales-Alexander J, et al. Comparison of subclinical carotid atherosclerosis in patients with psoriatic arthritis, psoriasis alone and controls [abstract]. Ann Rheum Dis. 2012; 71 (Suppl3): 572. 2012.
46. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008; 117(19): 2467-74.
47. Heffernan KS, Karas RH, Patvardhan EA, Jafri H, Kuvin JT. Peripheral arterial tonometry for risk stratification in men with coronary artery disease. Clin Cardiol 2010; 33(2): 94-8.
48. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010; 31(9): 1142-8.
49. Jensen PR, Zachariae C, Hansen P, Skov L. Normal endothelial function in patients with mild-to-moderate psoriasis: a case-control study. Acta Derm Venereol 2011; 91(5): 516-20.
50. Ardic I, Kaya MG, Yarlioglues M, et al. Impaired aortic elastic properties in normotensive patients with psoriasis. Blood Press 2010; 19(6): 351-8.
51. Bicer A, Acikel S, Kilic H, et al. Impaired aortic elasticity in patients with psoriasis. Acta Cardiol 2009; 64(5): 597-602.
52. Tam LS, Li EK, Shang Q, et al. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intimamedia thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis 2011; 70(4): 705-6.
53. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-alpha blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011; 31(3): 705-12.
54. Avgerinou G, Tousoulis D, Siasos G, et al. Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol 2011; 151(3): 382-3.
55. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012; 25(6): 644-50.
56. Angel K, Provan SA, Hammer HB, Mowinckel P, Kvien TK, Atar D. Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundam Clin Pharmacol 2011; 25(4): 511-7.
57. Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2010; 55(2): 333-8.
58. Mazzoccoli G, Notarsanto I, de Pinto GD, et al. Anti-tumor necrosis factor-alpha therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med 2010; 5(6): 495-500.
59. Bonifati C, Mussi A, Carducci M, et al. Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity. Acta Derm Venereol 1998; 78(1): 22-6.
60. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130(7): 1785-96.
61. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180(3): 1141-6.
62. Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010; 24(7): 789-96.
63. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157(6): 1249-51.
64. Garbaraviciene J, Diehl S, Varwig D, et al. Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. Exp Dermatol 2010; 19(8): 736-41.
65. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999; 141(6): 1054-60.
66. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115(10): 1285-95.
67. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115(5): 1111-9.
68. McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 2009; 6(6): 410-7.
69. Full LE, Monaco C. Targeting Inflammation as a Therapeutic Strategy in Accelerated Atherosclerosis in Rheumatoid Arthritis. Cardiovascular Therapeutics 2011; 29(4): 231-42.
70. Wu JJ, Poon KY, Channual JC, Shen AY. Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis. Arch Dermatol 2012: 1-7.
71. Sandqvist M, Nyberg G, Hammarstedt A, et al. Low adipocyte IRS-1 protein expression is associated with an increased arterial stiffness in non-diabetic males. Atherosclerosis 2005; 180(1): 119-25.
72. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994; 266(6 Pt 2): H2535-41.
73. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factoralpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106(17): 2184-7.
74. Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001; 116(5): 713-20.
75. Chen JX, Chen Y, DeBusk L, Lin W, Lin PC. Dual functional roles of Tie-2/angiopoietin in TNF-alpha-mediated angiogenesis. Am J Physiol Heart Circ Physiol 2004; 287(1): H187-95.
76. Markham T, Mullan R, Golden-Mason L, et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006; 54(6): 1003-12.